Pharmala Biotech Holdings Inc.

Equities

MDMA

CA71719L1067

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 11:25:12 03/07/2024 pm IST			5-day change	1st Jan Change
0.11 ^CAD	-4.35%		-12.00%	-21.43%

03/05	PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy	MT
23/04	Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla	CI

Pharmala Biotech Holdings Inc. Initiates Research At the University of Arkansas for Medical Sciences

January 17, 2022 at 10:59 pm IST

PharmAla Biotech Holdings Inc. announced that the company has initiated preclinical research on its patented novel chemical entities (NCEs) at the laboratory of Dr. William Fantegrossi at the University of Arkansas for Medical Sciences (UAMS).

Latest news about Pharmala Biotech Holdings Inc.

PharmAla Up Near 8% As Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy	03/05	MT
Red Light Holland Corp. Initiates Psilocybin Extraction Phase with PharmAla	23/04	CI
Pharmala Biotech Completes $750,000 Private Placement, Debt Settlement	19/04	MT
Pharmala Biotech Holdings Inc. announced that it has received CAD 0.75 million in funding	19/04	CI
Pharmala Biotech Holdings Inc. announced that it expects to receive CAD 0.75 million in funding	10/04	CI
PharmAla Biotech Provides Australian Update	05/04	MT
US Patent and Trademark Office Grants Patent Allowance to Pharmala Biotech Holdings Inc. for ALA-002 Composition	27/03	CI
Pharmala Biotech Holdings Inc. Allowance Granted for Ala-002 Composition by US Patent and Trademark Office	27/03	CI
PharmAla Biotech Signs Sale Agreement with Numinus Wellness	26/03	MT
Pharmala Biotech Holdings Inc. Signs Sale Agreement with Numinus	26/03	CI
PharmAla Says Patent Allowance Granted for P-1 Molecule by USPTO	20/03	MT
Pharmala Biotech Holdings Inc. Announces Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office	20/03	CI
PharmAla Biotech Holdings Inc. Announces Joint Venture with Cortexa Pty. Ltd	18/03	CI
PharmAla Named an Intellectual Property Ontario Client	22/02	MT
PharmAla Biotech Holdings Inc. Announces Data from its Computational Drug Discovery Program in the Scientific Journal ACS Chemical Neuroscience	20/02	CI
Listed Duo PharmAla and Red Light Holland to Collaborate on Medical Psilocybin Development	09/02	MT
PharmAla Biotech Holdings Inc. Enters into Consulting Relationship with Red Light Holland Corp	09/02	CI
PharmAla Reports Q1 Profit, Provides Business Update	31/01	MT
PharmAla up 41%, Granted Controlled Drugs & Substances Dealer's License by Health Canada	26/01	MT
PharmAla Biotech Holdings Inc. Receives A Controlled Drugs & Substances Dealer's License by Health Canada	25/01	CI
Pharmala Biotech Holdings Inc.'s PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance	08/01	CI
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules	15/11	MT
PharmAla Biotech Holdings Inc. Announces World's First Observational Trial to Assess Real-World Efficacy of MDMA Treatment	09/11	CI
PharmAla Biotech Received First Office Action for PharmAla-1 PCT Filing	25/23/25	MT
Pharmala Biotech Holdings Inc. Receives First Office Action for PharmAla-1 Pct Filing	25/23/25	CI

Chart Pharmala Biotech Holdings Inc.

Duration

Period

More charts

Company Profile

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.

Sector

Biotechnology & Medical Research

Calendar

26/07/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PHARMALA BIOTECH HOLDINGS INC.	-21.43%	72.97L
VERTEX PHARMACEUTICALS INCORPORATED	+15.58%	12TCr
REGENERON PHARMACEUTICALS, INC.	+16.60%	11TCr
ARGENX SE	+17.55%	2.62TCr
BIONTECH SE	-24.33%	1.9TCr
GENMAB A/S	-19.14%	1.57TCr
BEIGENE, LTD.	-17.95%	1.52TCr
WUXI APPTEC CO., LTD.	-46.81%	1.47TCr
SAREPTA THERAPEUTICS, INC.	+58.78%	1.46TCr
NEUROCRINE BIOSCIENCES, INC.	+4.91%	1.38TCr

Bio Therapeutic Drugs